New Methods in the Diagnosis of Cancer and Gene Therapy of Cancer Based on Nanoparticles

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2017 Jun 3

PMID 28574057

Citations 88

Authors

M A Zaimy

N Saffarzadeh

A Mohammadi

H Pourghadamyari

P Izadi

A Sarli

L K Moghaddam

S R Paschepari

H Azizi

S Torkamandi

J Tavakkoly-Bazzaz

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the leading cause of death in the world with the prevalence of >10 million mortalities annually. Current cancer treatments include surgical intervention, radiation, and taking chemotherapeutic drugs, which often kill the healthy cells and result in toxicity in patients. Therefore, researchers are looking for ways to be able to eliminate just cancerous cells. Intra-tumor heterogeneity of cancerous cells is the main obstacle on the way of an effective cancer treatment. However, better comprehension of molecular basis of tumor and the advent of new diagnostic technologies can help to improve the treatment of various cancers. Therefore, study of epigenetic changes, gene expression of cancerous cells and employing methods that enable us to correct or minimize these changes is critically important. In this paper, we will review the recent advanced strategies being used in the field of cancer research.

Citing Articles

Selective Up-Regulation of Tumor Suppressor Gene Retinoblastoma by Bisacridine Derivative Through Gene Promoter Quadruplex Structures for Cancer Treatment.

Lin X, Zhang J, Liang J, Ji D, Huang Z, Li D Int J Mol Sci. 2025; 26(4).

PMID: 40003883 PMC: 11855212. DOI: 10.3390/ijms26041417.

Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.

Marton E, Varga A, Domoszlai D, Buglyo G, Balazs A, Penyige A Cancers (Basel). 2025; 17(4).

PMID: 40002172 PMC: 11853212. DOI: 10.3390/cancers17040579.

Review: performance of jujube and its extracts in cancer: therapeutic, toxicity-reducing and potentiating effects.

Gou B, Chen G, Huang S, Ning N, Gu Q, Duan S Front Oncol. 2025; 15:1489974.

PMID: 39944835 PMC: 11814214. DOI: 10.3389/fonc.2025.1489974.

Advanced photoluminescent nanomaterials for targeted bioimaging of cancer cells.

Mohammadi T, Gheybalizadeh H, Rahimpour E, Soleymani J, Shafiei-Irannejad V Heliyon. 2025; 11(1):e41566.

PMID: 39850435 PMC: 11754178. DOI: 10.1016/j.heliyon.2024.e41566.

Composition analysis and mechanism of Guizhi Fuling capsule in anti-cisplatin-resistant ovarian cancer.

Dou L, Yan Y, Lu E, Li F, Tian D, Deng L Transl Oncol. 2024; 52():102244.

PMID: 39662450 PMC: 11683237. DOI: 10.1016/j.tranon.2024.102244.

References

Visone R, Croce C . MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8. PMC: 2671346. DOI: 10.2353/ajpath.2009.080794. View

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

Singhania R, Khairuddin N, Clarke D, McMillan N . RNA interference for the treatment of papillomavirus disease. Open Virol J. 2013; 6:204-15. PMC: 3547394. DOI: 10.2174/1874357901206010204. View

Kelly T, De Carvalho D, Jones P . Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010; 28(10):1069-78. PMC: 3022972. DOI: 10.1038/nbt.1678. View

LaVan D, McGuire T, Langer R . Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003; 21(10):1184-91. DOI: 10.1038/nbt876. View

Weiler J, Hunziker J, Hall J . Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 2005; 13(6):496-502. DOI: 10.1038/sj.gt.3302654. View

Jebali A, Kalantar S, Hekmatimoghaddam S, Saffarzadeh N, Sheikha M, Ghasemi N . Surface modification of tri-calcium phosphate nanoparticles by DOPE and/or anti-E6 antibody to enhance uptake of antisense of E6 mRNA. Colloids Surf B Biointerfaces. 2015; 126:297-302. DOI: 10.1016/j.colsurfb.2014.12.040. View

Zagar T, Vujaskovic Z, Formenti S, Rugo H, Muggia F, OConnor B . Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Int J Hyperthermia. 2014; 30(5):285-94. PMC: 4162656. DOI: 10.3109/02656736.2014.936049. View

10.

Davidson B, McCray Jr P . Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011; 12(5):329-40. PMC: 7097665. DOI: 10.1038/nrg2968. View

11.

Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A . Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011; 25(18):1915-27. PMC: 3185964. DOI: 10.1101/gad.17446611. View

12.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

13.

Reddy S, van der Vlies A, Simeoni E, Angeli V, Randolph G, ONeil C . Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007; 25(10):1159-64. DOI: 10.1038/nbt1332. View

14.

Rahman A, Yusuf S, Ewer M . Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine. 2008; 2(4):567-83. PMC: 2676818. View

15.

Yin H, Kanasty R, Eltoukhy A, Vegas A, Dorkin J, Anderson D . Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014; 15(8):541-55. DOI: 10.1038/nrg3763. View

16.

Orom U, Kauppinen S, Lund A . LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene. 2006; 372:137-41. DOI: 10.1016/j.gene.2005.12.031. View

17.

Robbins P, Ghivizzani S . Viral vectors for gene therapy. Pharmacol Ther. 1998; 80(1):35-47. View

18.

Bahman Bahramian M, Zarbl H . GENE impedance: a natural process for control of gene expression and the origin of RNA interference. J Theor Biol. 2005; 233(3):301-14. DOI: 10.1016/j.jtbi.2004.10.007. View

19.

Gutschner T, Diederichs S . The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9(6):703-19. PMC: 3495743. DOI: 10.4161/rna.20481. View

20.

Paula D, Bentley M, Mahato R . Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA. 2007; 13(4):431-56. PMC: 1831859. DOI: 10.1261/rna.459807. View